RELEVANCE OF THE ELIMINATION POLYMORPHISM OF THE GSTM1 AND GSTT1 GENE IN PATIENTS WITH LUPIC NEPHRITIS
DOI:
https://doi.org/10.18041/2390-0512/biociencias.1.6359Keywords:
SLE, Clinical features, Arthritis, Erythema, Lupus nephritisAbstract
Objective: To identify if the absence of the GSTM1 and / or GSTT1 genes is correlated with the response to cyclophosphamide and the presence of anti DNA in a patient with SLE. Methodology: An correlational cross study that included 46 patients with a diagnosis of systemic lupus erythematosus. (LES), who attended the rheumatology clinic of the Venezuelan Institute of Social Security- Central Hospital "Dr. Miguel Pérez Carreño ", during the period June 2016 - June 2017. Patients with SLE were classified according to the presence or absence of renal involvement (lupus nephritis). Each individual was extracted 5 mL of peripheral blood, from which the genomic DNA was extracted. The presence or absence of the GSTM1 and GSTT1 genes was determined using the multiplex polymerase chain reaction method with specific primers. Results: In the studied population (n = 46), 95.7% were women and only 4.3% men. The average age was 31 years, being mostly young women of childbearing age. The treatment of patients included the use of chloroquine (78%), mycophenolate (69.6%) and corticoids (38.7%). The GST genes were present, the GSTM1 gene with a frequency.
Downloads
References
2. Ghodke-Puranik Y , Niewold TB. Immunogenetics of systemic lupus erythematosus: A comprehensive review. J Autoimmun. 2015 Nov; 64:125-36.
3. Hong-Na W, Xiao-Ye Z., Ying Z., Qiong-Hong X., Lin-Yun L., Miao Zhao, Yuan-Cheng C., Jun X., et al, The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients, Clinical Immunology (2015), doi: 10.1016/j.clim.2015.07.010).
4. Hans-Joachim L, Agnes F Immunopathology of Lupus Nephritis. Semin Immunopathol. 2014 Jul;36(4):443-59.
5. Lisnevskaia L, Murphy G., Isenberg D Systemic Lupus Erythematosus. Lancet 2014; 384: 1878–88
6. Dilip S., Nidhi M., Sangita S., Swapan K N., Bishnuhari P. Oxidative stress and its biomarkers in systemic lupus erythematosus Shah et al. Journal of Biomedical Science 2014, 21:23.
7. Andras P Oxidative stress in the pathology and treatment of systemic lupus erythematosus Nat Rev Rheumatol. 2013 November; 9(11): 674–686. doi:10.1038/nrrheum.2013.147.
8. Pinheiro D, Rocha Filho C, Mundim C, Júnior M, Ulhoa C, Reis A, Ghedini P. Evaluation of glutathione S-transferase GSTM1 and GSTT1 deletion polymorphisms on type-2 diabetes mellitus risk. PLoS One. 2013 Oct 3; 8(10):e76262.
9. Petri M, Orbai A, Alarcón G, Gordon C, Merrill J, Fortin P. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86
10. Bunce M. PCR-SSP typing in histocompatibility testing. Bidwell and Navarrette C. Imperial Collage Press, London. 2000: 149-186
11. Gogtay N, Thatte U. Principles of Correlation Analysis. J Assoc Physicians India. Statistics for Researches. 2017: 65, 78-81.
12. Weening JJ, D’Agati VD. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. J Am Soc Nephrol 2004; 15:241-50.
13. Shah, D., Mahajan, N., Sah, S. et al. Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci 21, 23 (2014). https://doi.org/10.1186/1423-0127-21-23.
14. Peñaranda L, Mercado I, Caballero V, Márquez J, Velásquez C. Factores de riesgo predictores de falla a la terapia de inducción de nefritis lúpica en una cohorte de pacientes colombianos. Reumatol clin. 2014; 10 (3) 147 – 151.
15. Oliva J, Arroyo J, Oliva J, García M. Patrones de tinción de anticuerpos antinucleares identificados por Inmunofluorescencia indirecta en pacientes con enfermedad del tejido conectivo. Rev Med Hered. 2019; 30:33-39.
16. Zeineb Z, Mouna M, Mohamed El A, Amina B, Rajae E, Naima A, Mohcine B. Immunological and Clinical Characteristics of Systemic Lupus Erythematosus: A Series from Morocco. Biomed Res Int. 2018: 3139404.
17. Pons-Estel G, Wojdyla D, McGwin G, Magder L, Petri M, Pons-Estel B, Alarcón G. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. Lupus. 2014; 23(1):3-9.
18. Nyman E, Vaughan T, Desta B, Wang X, Barut V, Emmas C. Characteristics and Symptom Severity of Patients Reporting Systemic Lupus Erythematosus in the PatientsLikeMe Online Health Community: A Retrospective Observational Study. Rheumatol Ther. 2020 Mar; 7(1): 201–213.
19. Fulgeria C, Carpio D, Ardile L. Lesiones renales en el lupus eritematoso diseminado: ausencia de relación entre datos clínicos e histológicos. Nefrología 2018; 38(4):386–393.
20. Salimi S, Nakhaee A, Jafari M, Jahantigh D, Sandoogh M, Zakeri Z, et al. Polymorphisms and risk of systemic lupus erythematosus. Iran J Public Health 2015; (44): 812-821
21. Kang, Sohemy A, Cornelis M, Eny K, Bae S. Glutathione S-transferase genotype and risk of systemic lupus erythematosus in Koreans. Lupus (2005) 14, 381-384.
22. Shilong Z, Huang M, Yang X, Liang L, Wang Y, Romkes M, et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacology 2006 62:4 457–472.
23. Zhang J, Deng j, Zhang C, Lu Y, Liu L, Wua Q, et al Association of GSTT1, GSTM1 and CYP1A1 polymorphisms with susceptibility to systemic lupus erythematosus in the Chinese population. Clinica Chimica Acta 411 2010 878–881.
24. Lechun L, Dongyun L, Nong X, Guo M, Ma j, He L. The Null Polymorphism of the GSTM1/T1 Gene Is Not Associated with Susceptibility to Systemic Lupus Erythematosus: A Meta-Analysis. Mol Diagn Ther 2015 19:65–6.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
